Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
05 09 2022
05 09 2022
Historique:
received:
20
03
2022
accepted:
22
08
2022
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We investigate an HB vaccine consisting of large-HBsAg that overcomes the shortcomings of the current HB vaccine. Yeast-derived large-HBsAg is immunized into rhesus macaques, and the neutralizing activities of the induced antibodies are compared with those of the current HB vaccine. Although the antibodies induced by the current HB vaccine cannot prevent HBV infection with VEMs, the large-HBsAg vaccine-induced antibodies neutralize those infections. The HBV genotypes that exhibited attenuated neutralization via these vaccines are different. Here, we show that the HB vaccine consisting of large-HBsAg is useful to compensate for the shortcomings of the current HB vaccine. The combined use of these HB vaccines may induce antibodies that can neutralize HBV strains with VEMs or multiple HBV genotypes.
Identifiants
pubmed: 36064848
doi: 10.1038/s41467-022-32910-z
pii: 10.1038/s41467-022-32910-z
pmc: PMC9441830
doi:
Substances chimiques
Hepatitis B Antibodies
0
Hepatitis B Surface Antigens
0
Hepatitis B Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5207Informations de copyright
© 2022. The Author(s).
Références
J Virol. 1988 Aug;62(8):2836-44
pubmed: 2839705
Expert Rev Vaccines. 2003 Apr;2(2):197-203
pubmed: 12899571
Hepatol Commun. 2020 Dec 19;5(4):634-649
pubmed: 33860122
J Virol. 2013 Nov;87(22):12196-206
pubmed: 24006443
Cancer Sci. 2018 Jan;109(1):241-249
pubmed: 29121422
Nat Biotechnol. 2003 Aug;21(8):885-90
pubmed: 12833071
Hepatology. 2021 Feb;73(2):520-532
pubmed: 32446278
J Gastroenterol. 2017 Sep;52(9):1051-1063
pubmed: 28197802
J Biol Chem. 1992 Jan 25;267(3):1953-61
pubmed: 1370486
Vaccines (Basel). 2020 Aug 16;8(3):
pubmed: 32824318
Protein Expr Purif. 2011 Aug;78(2):149-55
pubmed: 21515381
Intervirology. 2014;57(3-4):141-50
pubmed: 25034481
Hepatology. 2015 Dec;62(6):1893-908
pubmed: 26239691
Am J Prev Med. 1998 Jul;15(1):1-8
pubmed: 9651632
Cell. 1986 Aug 1;46(3):429-36
pubmed: 3015414
Cancer Sci. 2015 Nov;106(11):1616-24
pubmed: 26310603
J Virol. 2007 Jun;81(11):5841-9
pubmed: 17376925
Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68
pubmed: 10704474
Lancet. 1990 Aug 11;336(8711):325-9
pubmed: 1697396
Front Microbiol. 2020 Dec 14;11:616023
pubmed: 33381105
Gut. 2015 Dec;64(12):1972-84
pubmed: 26048673
J Hepatol. 2019 Aug;71(2):289-300
pubmed: 31077792
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3086-91
pubmed: 24516163
Clin Infect Dis. 2016 Jun 1;62(11):1412-8
pubmed: 27009250
J Virol. 2020 Dec 9;:
pubmed: 33298539
Eur J Epidemiol. 2001;17(2):135-40
pubmed: 11599686
Gastroenterology. 2012 Aug;143(2):400-7
pubmed: 22580098
Gut. 2018 Feb;67(2):372-379
pubmed: 27797937
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-476
pubmed: 30982722
J Clin Invest. 1992 Dec;90(6):2543-7
pubmed: 1281839
Hepatology. 2009 May;49(5 Suppl):S45-55
pubmed: 19399792
Chin Med J (Engl). 2021 Oct 11;134(23):2825-2831
pubmed: 34636774
J Hepatol. 1991;13 Suppl 4:S105-7
pubmed: 1726588
Cell Mol Gastroenterol Hepatol. 2021;12(5):1583-1598
pubmed: 34352407